Detail

Keywords

Metabolism; Molecular Imaging; Oncology; Radioactive Tracers

Research interests

My research focuses on helping to understand the relevance of various cellular and metabolic pathways for proper organ function. Utilizing small amounts of a radioactively labeled substance, it is possible to image various receptors and a variety of peptides potentially involved in the metabolism and pathology of diseases and tumors in the field of nuclear medicine in which I work. Therefore, via molecular imaging targeting receptors and biochemical processes specifically involved in disease etiology and tumor pathogenesis, nuclear medicine plays a pivotal role in the field of endocrinology, oncology, cardiology, and brain metabolism.

Using the similar approach, but employing specific radionuclides suitable for therapy, radionuclide-labeled therapies have been developed that specifically target certain receptors that are overexpressed in certain disorder and tumor cells, thereby systemically destroying the local tumor and its distant metastases; a process called targeted theranostics.

Techniques, methods & infrastructure

Positron Emission Tomography-Computed Tomography/Magnetic Resonance Imaging employing various radio-labeled peptides targeting cells and specific receptors responsible for tumor and cellular metabolism at the molecular level.

Selected publications

1. Rasul, S. et al. (2019) ‘Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks’, European Journal of Nuclear Medicine and Molecular Imaging, 47(3), pp. 713–720. Available at: http://dx.doi.org/10.1007/s00259-019-04584-1.
2. Wollenweber, T. et al. (2021) ‘Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer’, Current Oncology, 28(5), pp. 3692–3704. Available at: http://dx.doi.org/10.3390/curroncol28050315.
3. Rasul, S. et al. (2023) ‘Direct Patlak Reconstruction of [68Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study’, International Journal of Molecular Sciences, 24(18), p. 13677. Available at: http://dx.doi.org/10.3390/ijms241813677.
4. Rasul, S. et al. (2018) ‘[18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery’, European Journal of Nuclear Medicine and Molecular Imaging, 45(12), pp. 2159–2169. Available at: http://dx.doi.org/10.1007/s00259-018-4045-9.
5. Rasul, S. et al., 2020. Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using 18F-FDG PET/MRI. BMJ Open Diabetes Research & Care, 8(1), p.e001135. Available at: http://dx.doi.org/10.1136/bmjdrc-2019-001135.